Open discussion

Clinical Cancer Research

Volumn 13, Issue 2 II, 2007, Pages

  Atkins, ^a   Rini, ^a   Flaherty, ^a   Figlin, ^a   George, ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ERLOTINIB; INTERFERON; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; VASCULOTROPIN ANTIBODY; VON HIPPEL LINDAU PROTEIN; ALPHA2B INTERFERON; INTERLEUKIN 2; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VASCULOTROPIN;

CANCER IMMUNOTHERAPY; CLINICAL TRIAL; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; NOTE; PRIORITY JOURNAL; ANGIOGENESIS; ARTHRALGIA; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CYTOLOGY; DRUG MEGADOSE; ENDOTHELIUM CELL; FATIGUE; HYPERTENSION; HYPOXIA;

CARCINOMA, RENAL CELL; CELL MOVEMENT; CELL PROLIFERATION; CLINICAL TRIALS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846868846     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2110     Document Type: Note

References (60)

1. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7:85-90.
2. Shuin T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res 1994;54:2852-5.
3. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994;91:9700-4.
4. Gnarra JR, Lerman MI, Zbar B, Linehan WM. Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis. Semin Oncol 1995;22:3-8.
5. Kondo K, Klco J, Nakamura E, Lechpammer M, Kaelin WG, Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46.
6. Brauch H, Hoeppner W, Jahnig H, et al. Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene. J Clin Endocrinol Metab 1997;82:4101-4.
7. Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer 1998;22:200-9.
8. Kondo K, Yao M, Yoshida M, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer 2002;34:58-68.
9. Kenck C, Wilhelm M, Bugert P, Staehler G, Kovacs G. Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 1996;179:157-61.
10. Kibel A, Iliopoulos O, DeCaprio JA, Kaelin WG, Jr. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 1995;269:1444-6.
11. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5.
12. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-41.
13. 2 sensing. Science 2001;292:464-8.
14. Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 2003;13:83-9.
15. 2-regulated prolyl hydroxylation. Science 2001;292:468-72.
16. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, Jr., Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996;93:10595-9.
17. Hu CJ, Iyer S, Sataur A, Covello KL, Chodosh LA, Simon MC. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in stem cells. Mol Cell Biol 2006;26:3514-26.
18. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
19. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12.
20. Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain RK. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1α→ hypoxia response element→ VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 2000;60:6248-52.
21. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
22. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-54.
23. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-8.
24. Helmlinger G, Endo M, Ferrara N, Hlatky L, Jain RK. Formation of endothelial cell networks. Nature 2000;405:139-41.
25. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 1986;46:5629-32.
26. Collins PD, Connolly DT, Williams TJ. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Br J Pharmacol 1993;109:195-9.
27. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
28. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108:2369-79.
29. Wu HM, Huang Q, Yuan Y, Granger HJ. VEGF induces NO-dependent hyperpermeability in coronary venules. Am J Physiol 1996;271:H2735-9.
30. Hippenstiel S, Krull M, Ikemann A, Risau W, Clauss M, Suttorp N. VEGF induces hyperpermeability by a direct action on endothelial cells. Am J Physiol 1998;274:L678-84.
31. Lal BK, Varma S, Pappas PJ, Hobson RW II, Duran WN. VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways. Microvasc Res 2001;62:252-62.
32. Bates DO, Lodwick D, Williams B. Vascular endothelial growth factor and microvascular permeability. Microcirculation 1999;6:83-96.
33. Ross R. Angiogenesis: successful growth of tumours. Nature 1989;339:16-7.
34. Li VW, Folkerth RD, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994;344:82-6.
35. Brattstrom D, Bergqvist M, Larsson A, et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 1998;18:1123-7.
36. Yamamoto Y, Toi M, Kondo S, et al. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996;2:821-6.
37. Salven P, Ruotsalainen T, Mattson K, Joensuu H. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998;79:144-6.
38. Gasparini G, Toi M, Gion M, et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J Natl Cancer Inst 1997;89:139-47.
39. Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995;87:1237-45.
40. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9.
41. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335-45.
42. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80.
43. Rowe DH, Huang J, Kayton ML, et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 2000;35:30-2; discussion 32-33.
44. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-34.
45. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996;93:14765-70.
46. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 2004;10:6367-70S.
47. Viloria-Petit A, Crombet T, Jothy S, et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001;61:5090-101.
48. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol 2005;23:7889-96.
49. Bukowski RM, Kabbinavar F, Figlin RA, et al. Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC) [abstract 4523]. J Clin Oncol 2006;24:222s.
50. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. Cancer and Leukemia Group B 90206: a randomized phase III trial of interferon-α or interferon-α plus antivascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10:2584-6.
51. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
52. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963-70.
53. Posadas E, Kwitkowski V, Liel M. Clinical synergism from combinatorial VEGF signal transduction inhibition in patients with advanced solid tumors: early results from a phase I study of sorafenib (BAY 43-9006) and bevacizumab. Eur J Cancer Suppl 2005;3:419.
54. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-8.
55. Konner J, Dupont J. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF Trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer 2004;4:S81-5.
56. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003;9:802-11.
57. Frischer JS, Huang J, Serur A, et al. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int J Oncol 2004;25:549-53.
58. Dupont J, Koutcher J. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients with advanced solid malignancies. Proc Am Soc Clin Oncol 2004;23.
59. Dupont JR, Spriggs D. Safety and pharmacokinetic of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors. Proc Am Soc Clin Oncol 2005;23.
60. Lockhart A, Muruganandham M, Schwartz L. Pharmacodynamic indicators of VEGF trap activity in patients with advanced solid tumors. Clin Cancer Res 2005;11.